Skip to main content

ZENEO® Adrenaline Needle-free adrenaline pre-filled autoinjector rescues you from an anaphylactic shock

Project description

A needle-free shot of adrenaline

Anaphylactic shock is an extreme allergic reaction that needs to be treated immediately with a shot of epinephrine (adrenaline) to reverse the symptoms. Many people at risk of anaphylaxis carry an autoinjector – a combined syringe and concealed needle that injects a single dose of medication. This needle-based drug delivery device may soon be replaced by a needle-free alternative. Crossject’s ZENEO device permits needle-free injection of the drug in emergency situations. Under the EU-funded ZENEO project, the company plans to launch ZENEO® Adrenaline on the market by the end of 2021. It estimates a turnover of EUR 136 million and a profit of EUR 124 million by the fifth year of commercialisation.

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-1

Coordinator

CROSSJECT
Net EU contribution
€ 50 000,00
Address
6 Rue Pauline Kergomard Zac Parc Mazen Sully
21000 Dijon
France

See on map

Region
Bourgogne-Franche-Comté Bourgogne Côte-d’Or
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 21 429,00